We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




PARP-Inhibitors Reduce Damage in Some Neurological Disorders

By LabMedica International staff writers
Posted on 20 Aug 2018
Print article
Image: In cells under duress, stress granules (in magenta) form outside of the nucleus (in blue). TDP-43 protein in green (arrow) that cannot bind to polyADP ribose (PAR) builds up in large clumps distinct from stress granules (Photo courtesy of Leeanne McGurk, University of Pennsylvania).
Image: In cells under duress, stress granules (in magenta) form outside of the nucleus (in blue). TDP-43 protein in green (arrow) that cannot bind to polyADP ribose (PAR) builds up in large clumps distinct from stress granules (Photo courtesy of Leeanne McGurk, University of Pennsylvania).
A recent study found that blocking the activity of the poly(ADP-ribose)polymerase (PARP) family of enzymes reduced the amount of harmful TDP-43 (transactive response DNA binding protein) structures in brain cells under stress and slowed or prevented development of cytoplasmic inclusions found in neurological disorders such as amyotrophic lateral sclerosis (ALS), and some forms of frontotemporal degeneration (FTD).

In ALS and FTD, cytoplasmic aggregates of hyperphosphorylated TDP-43 accumulate and co-localize with some stress granule components, but how pathological TDP-43 aggregation is transferred to the nucleus remains unknown.

Investigators at the University of Pennsylvania (Philadelphia, USA) used cell cultures and a Drosophila (fruit fly) model to show that downregulation of the enzyme tankyrase, a PAR polymerase, reducedTDP-43 accumulation in the cytoplasm and potently inhibited neurodegeneration. They established that TDP-43 non-covalently bound to PAR via PAR-binding motifs embedded within its nuclear localization sequence. PAR binding promoted liquid-liquid phase separation of TDP-43 in vitro and was required for TDP-43 accumulation in stress granules in mammalian cells and neurons. Stress granule localization initially protected TDP-43 from disease-associated phosphorylation, but upon long-term stress, stress granules eventually dissolved, leaving behind aggregates of phosphorylated TDP-43.

The investigators reported in the August 9, 2018, online edition of the journal Molecular Cell that PARP inhibitors, which stop PAR from being generated, reduced the amount of harmful TDP-43 structures localized into stress granules. This reduced TDP-43-linked pathology and neurodegeneration and could be of use therapeutically for the treatment of ALS and FTD.

“Given the lack of treatment options, we are excited by these experiments that help elucidate molecular events that could lead to new therapeutics,” said senior author Dr. Nancy Bonini, professor of biology at the University of Pennsylvania.

Related Links:
University of Pennsylvania

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.